Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients [Yahoo! Finance]
Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF)
NASDAQ:AMEX Investor Relations:
ir.canfite.com
Company Research
Source: Yahoo! Finance
Patient enrolment for Phase IIb study is ongoing in Europe and Israel RAMAT GAN, Israel, April 03, 2024 BUSINESS WIRE )--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), for the Company's ongoing Phase IIb clinical study. Can-Fite's drug candidate, Namodenoson, has been shown to reduce hepatic steatosis, inflammation, and fibrosis, as well as body weight reduction, in a Phase IIa clinical study where data have been already published in a peer scientific journal ( Link to Manuscript ). Currently Can-Fite is enrolling patients for a Phase IIb clinical study in Europe and in Israel and is seeki
Show less
Read more
Impact Snapshot
Event Time:
CANF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CANF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CANF alerts
High impacting Can-Fite Biopharma Ltd Sponsored ADR (Israel) news events
Weekly update
A roundup of the hottest topics
CANF
News
- Can-Fite BioPharma Ltd. (NYSE: CANF) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NVAccesswire
- Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal [Yahoo! Finance]Yahoo! Finance
- Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific JournalBusiness Wire
- Can-Fite BioPharma Ltd. (NYSE: CANF) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
CANF
Sec Filings
- 4/25/24 - Form 6-K
- 4/15/24 - Form 6-K
- 4/10/24 - Form EFFECT
- CANF's page on the SEC website